North America regenerative medicines market is expected to reach USD 13.67 billion by 2023 from USD 5.38 billion in 2018, growing at a CAGR of 20.50% during the forecast period 2018-2023. Regenerative medicines repair, replace or regenerate human cells, tissues, or organs affected due to injury, disease, aging processes, congenital defects, and damage due to trauma. These medicines restore normal functions of cells & tissues. These medicines are available in different types such as genes, somatic cells, stem cells, and other types. Some of these medicines (such as stem cells) have the ability to proliferate, differentiate thereby restore the original structure of cells or tissues or organs. Regenerative medicines are used in a varied range of degenerative disorders include cardiovascular, neurodegenerative diseases, dermatology, and orthopedic, among others. Majority of the researchers aim to focus on the development of innovative technologies to provide better regenerative medicines and effective healthcare treatment solutions to patients.
Growing advancements in stem cell therapy & tissue engineering technologies, increasing demand for bone & joint reconstructive surgeries, rising adoption of regenerative medicines utilization, growing number of new product launches in this market, presence of huge cell therapy products, rising funding from NIH & BARDA in the U.S. for the research & development, and increasing development of regenerative medicines in Canada are driving the growth of regenerative medicines market in North America. However, stringent regulatory pathways for the approval of cell based products and presence of effective ethical regulations for the usage of cell-based products are expected to restrain the growth of regenerative medicines market in North America.
North America regenerative medicines market is segmented based on product, therapy, and application. Based on product, the market is further sub-segmented as cell-based products and acellular products. Of these, cell-based products segment is estimated to account for larger share of North America regenerative medicines market by product in 2016. Further, Cell-based products segment is classified as autologous and allogeneic products. Based on therapy, the market is segmented as cell therapy, gene therapy, tissue engineering, and immunotherapy. Of these, cell therapy is estimated to command the highest share of North America regenerative medicines market by therapy in 2016.
Based on application, the market is segmented as orthopedic & musculoskeletal spine, dermatology, central nervous system, cardiovascular, oncology, diabetes, and other applications. Among these, orthopedic & musculoskeletal spine is estimated to command the largest share of North America regenerative medicines market by application in 2016.
On the basis of geographical areas, North America regenerative medicines market is segmented as U.S., and Canada. U.S., accounted for larger share of the North America regenerative medicines market in 2016, whereas Canada is estimated to grow at a higher CAGR during the forecast period 2016-2021.
The key players in regenerative medicines market such as, Vertex Pharmaceuticals Incorporated (U.S.), Acelity L.P. Inc. (U.S.), Celgene Corporation (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), NuVasive, Inc. (U.S.), Vericel Corporation (Genzyme) (U.S.), Japan Tissue Engineering Co., Ltd. (Japan), Cytori Therapeutics Inc. (U.S.), Advantagene, Inc. (U.S.), and Mesoblast Ltd. (Australia).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Introduction
5.2 Product
5.2.1 Introduction
5.2.2 Cell-Based Products
5.2.2.1 Autologous Cell-Based Products
5.2.2.2 Allogeneic Cell-Based Products
5.2.3 Acellular Products
5.3 Therapy
5.3.1 Introduction
5.3.2 Cell Therapy
5.3.3 Gene Therapy
5.3.4 Tissue Engineering
5.3.5 Immunotherapy
5.4 Application
5.4.1 Introduction
5.4.2 Orthopedic & Musculoskeletal Spine
5.4.3 Dermatology
5.4.4 Cardiovascular
5.4.5 Central Nervous System
5.4.6 Oncology
5.4.7 Diabetes
5.4.8 Other Applications
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Vertex Pharmaceuticals Incorporated (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Acelity L.P. Inc. (U.S.)
8.3 Celgene Corporation (U.S.)
8.4 StemCells, Inc. (U.S.)
8.5 Organogenesis Inc. (U.S.)
8.6 NuVasive, Inc. (U.S.)
8.7 Vericel Corporation (Genzyme) (U.S.)
8.8 Cytori Therapeutics Inc. (U.S.)
8.9 Advantagene, Inc. (U.S.)
8.10 Mesoblast Ltd. (Australia)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
